Hologic Inc. is slated to sell its profitable blood screening business, which accounted for almost 20 percent of the Marlborough, Mass. company's diagnostic revenues in fiscal 2016. The price is $1.85 billion in cash, which is much richer comparatively than other recent diagnostic acquisition comps, at least one Wall Street analyst noted. The business will be going to Hologic's longstanding partner, Barcelona-based Grifols S.A., which is already responsible for marketing these blood screening products while Hologic is primarily responsible for manufacturing and R&D. Under a deal that originally dates to 1998 under predecessor companies, Grifols...

Hologic Inc.is slated to sell its profitable blood screening business, which accounted for almost 20 percent of the Marlborough, Mass. company's diagnostic revenues in fiscal 2016. The price is $1.85 billion in cash, which is much richer comparatively than other recent diagnostic acquisition comps, at least one Wall Street analyst noted.